Multiple biological targets via ginsenosides

"Multiple biological targets via ginsenosides" refers to the broad, multi-target actions of ginsenosides, steroidal saponins from ginseng (Panax species), rather than a single discrete therapeutic target like a receptor or enzyme. Over 150 ginsenosides, classified mainly as protopanaxadiol (PPD, e.g., Rb1, Rg3) or protopanaxatriol (PPT, e.g., Rg1, Re) types, exert effects through diverse mechanisms including agonism of glucocorticoid and estrogen receptors, modulation of NMDA and serotonin receptors, and regulation of pathways like NF-κB, AMPK, and PI3K/Akt.[1][3][4] These compounds demonstrate neuroprotective, anti-inflammatory, antioxidant, and anti-tumor activities, often requiring gut biotransformation (e.g., to compound K) for enhanced potency in mammals.[1][2] In disease contexts, they improve insulin sensitivity and glucose uptake in diabetes, inhibit cancer cell proliferation and invasion, protect against ischemia-reperfusion injury, and reduce neuroinflammation in models of Alzheimer's and Parkinson's.[2][4] Ginsenosides show promise as adjuvants, enhancing chemotherapy efficacy in lung cancer or renal function in chronic kidney disease, with a favorable safety profile marked by low toxicity but challenges in bioavailability.[2][3] Their polypharmacology explains ginseng's wide therapeutic range across cancer, metabolic, neurodegenerative, and cardiovascular disorders, positioning them as candidates for multi-target therapies.[1][7]

Other names

Ginsenosidesprotopanaxadiol-type ginsenosidesRb1Rb2Rb3RcRdRg3Rh2protopanaxatriol-type ginsenosidesReRfRg1Rg2Rh1compound KPDPTover 150 ginsenoside congeners

Agonism of steroid receptors (GR, ER) with cross-talk (e.g., IGF-1R); inhibition of RTK, NMDA, 5-HT, AChR; modulation of Ca2+ channels; activation/inhibition of pathways (PI3K/Akt, AMPK, NF-κB, STAT3/PPARγ); reduction of gluconeogenesis (via AMPK/FOXO1); inhibition of SGLT1/GLUTs; anti-apoptotic effects (bcl-2 upregulation); MMP-9 inhibition for anti-invasion